In this podcast, Medicom’s correspondent covers 6 presentations held at the American Thoracic Society (ATS.21), held 14-19 May 2021. The topics discussed are:
- The Zephyr 1 study: benralizumab treatment in patients with asthma demonstrated a 55% reduction of exacerbations in a real-world setting
- nintedanib initiation among patients newly diagnosed with idiopathic pulmonary fibrosis
- Cystic Fibrosis patients with advanced lung disease benefit from triple therapy
- Tobacco biomarkers do not improve lung cancer prediction
- Results of the phase 3 NAVIGATOR trial
- LIBERTY ASTHMA VOYAGE trial showed efficacy for dupilumab
Posted on
Table of Contents: ATS 2021
Featured articles
Letter from the Editor
COVID-19: What Pulmonologists Need to Know
Antibody treatment for COVID-19: a combination is successful
Air pollution: an underestimated negative prognostic factor for COVID-19
Healthcare workers vulnerable to SARS-CoV-2 infections
Genetic risk variants responsible for COVID-19 predisposition
Asthma – An Update
“As-needed” inhaled corticosteroid therapy for mild asthma – what is the evidence?
IL-4/13 blocker successful in treatment of paediatric moderate-to-severe asthma
Benralizumab lives up to its phase 3 results in real-world findings
Tezepelumab – good success rates in various types of severe asthma
Sleep Disorders – An Underestimated Problem
OSA: A risk factor for earlier cognitive decline
Subgroup of patients with high heart rate response and coronary artery disease benefit from CPAP
Association between positive airway pressure treatment adherence and COVID-19 infection rates
COPD – What Is New
Possible aetiologies for COPD exacerbations – more evidence is needed
Does COPD plus COVID-19 equal higher mortality?
Biomarkers for acute exacerbations in COPD are required
Severe exacerbations: A key driver of all-cause mortality in COPD patients
Men and women with COPD differ in many ways
Younger adults with COPD at higher health risk than previously thought
Metabolic Dysregulation and Lung Disease
Obesity: A risk factor for new-onset asthma and worse asthma control
Metabolic dysfunction and lung disease: children are no small adults
Best of the Posters
Air pollution in winter linked to more hospital admissions in ILD patients
Tobacco biomarkers do not improve prediction of lung cancer risk
Vaping identified as risk factor for asthma
site created by:
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy